Nuvie Bio is a clinical‑stage biopharmaceutical company developing NVI‑100, a first‑in‑class water‑soluble peptide antagonist of the CGRP receptor for acute migraine treatment.
Funding
Funding not disclosed
Founders
Product
Problem
Current acute migraine treatments force a trade‑off between rapid pain relief and tolerability, leaving many patients without a therapy that provides both fast onset and a low side‑effect profile. Existing options often have delayed absorption, limited efficacy consistency, or significant drug‑drug interaction risks.
Solution
Nuvie Bio is developing NVI‑100, a first‑in‑class water‑soluble peptide antagonist of the calcitonin gene‑related peptide (CGRP) receptor, formulated for low‑volume subcutaneous injection via an autoinjector. The peptide’s rapid renal clearance minimizes hepatic metabolism, reducing interaction potential and improving tolerability. By delivering a fast‑absorbing, high‑efficacy CGRP blockade, NVI‑100 aims to provide acute migraine relief within minutes while maintaining a safety profile superior to existing oral or injectable therapies. The approach leverages proprietary peptide technology to create a new class of migraine medication that combines speed, consistent efficacy, and enhanced safety.
Target Audience
Primary customers are neurologists, headache specialists, and migraine clinics seeking an acute treatment that offers both rapid pain relief and a favorable safety profile for patients who have unmet needs with current therapies.
Features
- Water‑soluble peptide designed for low‑volume subcutaneous formulation
- Autoinjector delivery enabling rapid absorption and onset of relief
- CGRP receptor antagonism with high binding affinity for consistent efficacy
- Primary renal clearance to limit hepatic drug‑drug interactions
- Engineered for minimal adverse events and improved tolerability compared to small‑molecule CGRP antagonists